1. Scrip
  2. >>Business
  3. >>Financing

ElevateBio Raises $401m To Fund Its Own And Partners’ Future Cell And Gene Therapy Needs

$1.3bn Invested In R&D, Manufacturing One-Stop Shop To Date

 
• By Mandy Jackson

ElevateBio closed a series D venture capital round and revealed a potentially multibillion-dollar deal between its Life Edit subsidiary and Novo Nordisk as demand for its cell and gene therapy capabilities grow.

DNA helix 3D model
ElevateBio has gene editing, iPSC, vector, RNA and cell technology platforms • Source: Shutterstock

ElevateBio, LLC launched in 2019 as a cell and gene therapy R&D and manufacturing hub for its subsidiary companies and partners, and with demand for its know-how growing, the firm has raised $410m in series D venture capital to keep the momentum going. Alongside the new financing, ElevateBio announced on 24 May that its subsidiary company Life Edit Therapeutics, Inc. has entered into a collaboration with Novo Nordisk A/S to develop gene-editing therapies.

More from Financing

AIRNA To Take RNA Editing Into The Clinic With $155m Series B Round

 
• By Mandy Jackson

CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.

Isomorphic Adds To Growing AI War Chest With First External Funding Round

 
• By Alaric DeArment

The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.

Finance Watch: European And Japanese Biotechs See VC Investor Interest In March

 
• By Mandy Jackson

Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.

Japan T-Reg Venture RegCell Raises New Funds, Relocates To US

 
• By Lisa Takagi

Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.

More from Business

AIRNA To Take RNA Editing Into The Clinic With $155m Series B Round

 
• By Mandy Jackson

CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.

Will They Or Won’t They? Tariff Question Looms For Drugmakers

 
• By Jessica Merrill

Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.

Cerevance To Focus On Parkinson’s Adjunctive Therapy After Phase II Miss

 
• By Joseph Haas

After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.